These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32064280)

  • 1. Is there a difference in FDG PET findings of invasive ductal carcinoma of the breast with and without coexisting DCIS?
    Sarikaya I; Sarikaya A; Albatineh AN; Tastekin E; Sezer YA
    Asia Ocean J Nucl Med Biol; 2020; 8(1):27-35. PubMed ID: 32064280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the correlation between FDG PET findings of IDC breast carcinoma and histopathology of coexisting ductal carcinoma in-situ.
    Sarikaya I; Sarikaya A; Albatineh AN; Tastekin E; Sezer YA
    Nucl Med Rev Cent East Eur; 2022; 25(1):6-11. PubMed ID: 35137931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological Features of Ductal Carcinoma
    Fujii T; Yanai K; Tokuda S; Nakazawa Y; Kurozumi S; Obayashi S; Yajima R; Hirakata T; Kuwano H
    Anticancer Res; 2017 Sep; 37(9):5053-5056. PubMed ID: 28870933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F-18 fluoride uptake in primary breast cancer.
    Sarikaya I; Sharma P; Sarikaya A
    Ann Nucl Med; 2018 Dec; 32(10):678-686. PubMed ID: 30178199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
    Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
    J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Breast MRI and (18)F-FDG PET/CT for the Preoperative Staging of Invasive Lobular Carcinoma versus Ductal Carcinoma.
    Jung NY; Kim SH; Kim SH; Seo YY; Oh JK; Choi HS; You WJ
    J Breast Cancer; 2015 Mar; 18(1):63-72. PubMed ID: 25834613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axillary Lymph Node-to-Primary Tumor Standard Uptake Value Ratio on Preoperative (18)F-FDG PET/CT: A Prognostic Factor for Invasive Ductal Breast Cancer.
    Kim YH; Yoon HJ; Kim Y; Kim BS
    J Breast Cancer; 2015 Jun; 18(2):173-80. PubMed ID: 26155294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ.
    Yoon HJ; Kim Y; Kim BS
    Eur Radiol; 2015 Dec; 25(12):3648-58. PubMed ID: 26063655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
    Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
    J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma, invasive ductal carcinoma coexisted with invasive micropapillary carcinoma, and invasive ductal carcinoma coexisted with ductal carcinoma in situ: A retrospective cohort study.
    Guan X; Xu G; Shi A; Zou Y; Zhan Y; Fan Z; Dong Y
    Medicine (Baltimore); 2020 Dec; 99(50):e23487. PubMed ID: 33327281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
    Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
    J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
    Wong H; Lau S; Leung R; Chiu J; Cheung P; Wong TT; Liang R; Epstein RJ; Yau T
    Med Oncol; 2012 Sep; 29(3):1536-42. PubMed ID: 21983862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of primary tumor SUV
    Yoo J; Yoon HJ; Kim BS
    Ann Nucl Med; 2017 Jan; 31(1):19-28. PubMed ID: 27645144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study.
    Fujioka T; Kubota K; Toriihara A; Machida Y; Okazawa K; Nakagawa T; Saida Y; Tateishi U
    World J Radiol; 2016 Aug; 8(8):743-9. PubMed ID: 27648168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ductal carcinoma in situ and ductal carcinoma in situ with microinvasion: correlation of FDG uptake with histological and biological prognostic factors.
    Seo YY; Yoo IR; Park SY; Oh JK; Kim SH; Sohn HS
    Breast Cancer; 2017 May; 24(3):353-361. PubMed ID: 27312540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective.
    Lee WP; Shetty SS; Seah CMJ; Tan PT; Tan SM
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1646. PubMed ID: 35892151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses.
    Ruszczyk M; Zirpoli G; Kumar S; Bandera EV; Bovbjerg DH; Jandorf L; Khoury T; Hwang H; Ciupak G; Pawlish K; Schedin P; Masso-Welch P; Ambrosone CB; Hong CC
    Cancer Causes Control; 2016 Feb; 27(2):183-98. PubMed ID: 26621543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.